Merck & Co. Signs Multibillion-Dollar Deal with Eisai for Lenvima®
By Heather Cartwright
Pharma Deals Review: Vol 2018 Issue 3 (Table of Contents)
Published: 20 Mar-2018
DOI: 10.3833/pdr.v2018.i3.2315 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In another attempt to expand the use of Keytruda® (pembrolizumab) beyond patients whose cancers express high levels of PD-L1 (programmed death ligand-1), Merck & Co...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS